



Supplemental Figure 2. MCC-UP status predicts better survival among non-immunosuppressed patients with either stage IIIB or IV disease. Panel **A** depicts MCC-specific survival **B** illustrates overall survival and **C** indicated recurrence-free survival for 92 patients with stage IIIB MCC by unknown primary status. Panel **D** describes MCC-specific survival for 19 patients with stage IV MCC. MCC-specific survival analyses was completed using a competing-risks regression model with the competing risk being defined as death by all causes except MCC. Overall and recurrence-free survival was performed using the Cox-proportional hazards model.